Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic
about
A research agenda for helminth diseases of humans: intervention for control and eliminationSchistosomiasis vaccinesWhy the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A reviewNovel therapeutic and prevention approaches for schistosomiasis: reviewSchistosomiasis vaccines: where do we stand?Do schistosome vaccine trials in mice have an intrinsic flaw that generates spurious protection data?An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areasEvaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque modelUse of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities.Complement plays a minimal role in Sm-p80-mediated protection against Schistosoma mansoni.Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine.Schistosomiasis chemotherapy.Bilharzia: Pathology, Diagnosis, Management and ControlHuman Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigensImmunology of human schistosomiasis.Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.Schistosome Vaccine Adjuvants in Preclinical and Clinical Research.Still hope for schistosomiasis vaccineSm-p80-based schistosomiasis vaccine mediated epistatic interactions identified potential immune signatures for vaccine efficacy in mice and baboons.Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.Development of a schistosomiasis vaccine.Cross-species protection: Schistosoma mansoni Sm-p80 vaccine confers protection against Schistosoma haematobium in hamsters and baboons.Urinary schistosomiasis.Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials.Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.Longevity of Sm-p80-specific antibody responses following vaccination with Sm-p80 vaccine in mice and baboons and transplacental transfer of Sm-p80-specific antibodies in a baboon.The self-curing phenomenon of schistosome infection in rhesus macaques: insight from in vitro studies.
P2860
Q21562256-A4CF8212-2A91-4E7A-B847-93F19613CF4CQ24598949-84E32152-2566-4572-8E7C-1C2C2B31888FQ26800061-9189EC4E-6B1F-4F94-9C19-AA8F2871F625Q27008897-74B6A3B3-5B6D-423F-A444-FCFB31B31B6DQ28066042-44E00D93-AA5A-4354-8F3A-4329B5040164Q28073949-23E4C9CB-61F1-46FE-B8F2-B1417EEC2B84Q28541675-4D04E6D0-5501-4253-BFCE-9E705039E3CEQ28544990-0DADA377-F01B-4A05-9FBC-7465025DFBAAQ33684408-D46EEF72-D7E3-433D-9EFD-A5C1B551A177Q33808603-F433D4C0-A1FE-4B6B-8753-0207902C5DF0Q34033792-2298DF0F-5301-442C-8ACB-EAD78236463DQ34290786-BF7D2F2D-8093-40D8-9004-21E632110253Q34354490-AA6D5E2A-07A4-4C61-AA74-8D5974354A73Q34400053-B2D10716-EE92-4AE8-B66F-A192216EFE33Q34563567-528FC513-8015-4632-8FD8-D07047C0A2C5Q34782228-B4B011B6-DC8B-464D-AFB9-723C3E5F6B8EQ35569944-AC01FD77-31B6-4A3A-B95E-8C34F8E3601EQ35611969-E2FB371F-9BFA-4161-AD21-43DF96ED62B4Q35826651-55455FE3-1CD7-4E60-A403-FA19E0F3EE9BQ36256373-C56A8539-2D31-449B-A26E-5D651484816DQ36278786-FBCB839F-11C9-48D2-A4DE-21290AD75AB4Q36368518-5ECC96FD-2691-4A99-8A53-E7AA1385C4BFQ37350747-31949A62-D099-40F3-AA27-BF3B3D7C177AQ37603033-46E9D3DD-176E-4661-B086-7E8DBD0D0441Q38182412-438E1EC5-8070-4612-B18F-706C3E7F483FQ39014289-9B65883B-BDDC-4FC3-920B-592C88999CBAQ39164396-5C77E522-44F0-4885-9908-ACEADEC41C5CQ39627135-93CE8FAC-410D-4E3B-A5A5-F324FF421F99Q47294803-60475AEF-5E71-4286-99D3-205A6C170597
P2860
Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@ast
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@en
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@nl
type
label
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@ast
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@en
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@nl
prefLabel
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@ast
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@en
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@nl
P2093
P2860
P3181
P356
P1476
Preclinical prophylactic effic ...... ere schistosomiasis is endemic
@en
P2093
Afzal A Siddiqui
Afzal Ahrorov
David W Carey
Gary L White
Lisa Ganley-Leal
Pauline N M Mwinzi
Raymond T Damian
Roman F Wolf
Ronald C Kennedy
P2860
P304
P3181
P356
10.1093/INFDIS/JIR545
P407
P5008
P577
2011-11-01T00:00:00Z